GSK smart to focus on partners for M&A, analysts say; AZ sells Loughborough site to plastics firm;

 @FiercePharma: Another German drugmaker in takeover talks: Riemser may pick shortlist by next week--BloombergStory | Follow @FiercePharma

> GlaxoSmithKline ($GSK) may avoid buying "lemons" by choosing from among its collaborators for buyouts, analysts tell Bloomberg. More

> Failing to unload its Loughborough, England, site to a life sciences buyer, AstraZeneca ($AZN) sold the property to the plastics recycler Jayplas. Article

> APP Pharmaceuticals nabbed three injectable generic products from Nexus Pharmaceuticals, including a copycat version of the UCB seizure drug Keppra. Item

> Danish pharma Lundbeck said it would launch an American Depositary Receipt via Deutsche Bank with ADRs trading on the U.S. over-the-counter market. Story

> Moody's hiked its credit rating on Mylan ($MYL), citing expectations for strong sales growth; its Ba1 rating is still below investment grade. News

> The Bristol-Myers Squibb Foundation said it would spend $15 million over 5 years to expand its Together on Diabetes initiative in China and India. Report

Biotech News

 @FierceBiotech: Vitamin D boosts TB shot as cancer therapy. More | Follow @FierceBiotech

 @RyanMFierce: Pfizer brings Lipitor brand to mobile app stores. Report | Follow @RyanMFierce

 @JohnCFierce: So Globe's verastem coverage says best-case scenario is start trials in a year, products available in four. A three-year cancer stem cell program? Ha. | Follow @JohnCFierce

> J&J loses key FDA panel vote on Xarelto. Item

> European pharmas join forces on $285M antibiotics collaboration. News

> Sanofi chief highlights high hopes for liver cancer drug. Story

> Upstart biotech lures Vertex founder out of retirement. Report

Medical Device News

 @FierceMedDev: HeartWare gained expanded European approval for its HVAD implant. Trials continue in the U.S., however. Story | Follow @FierceMedDev

 @MarkHFierce: Folks, there's still time to submit your nominations for the FierceMedicalDevices Fierce 15 private device developers. Survey | Follow @MarkHFierce

> Orrin Hatch pulls device tax repeal amendment from user fee bill. Report

> Once spectrum is approved, wireless patient monitors still face obstacles. Article

> Alere recalls thousands of cardiac diagnostic tests. More

> House Republicans push for tax-repeal vote. Item

Pharma Manufacturing News

 @EricPFierce: FDA to Crescendo: We told you so. Marshals seize steroid gel from California firm that was selling unapproved drug. Report | Follow @EricPFierce

> FDA may impose more QA checks on heparin makers. Story

> Recipharm snags $114 million loan, says its shopping. Article

> Heart attack test alert from Alere. More

> FDA takes aim at Spanish drugmaker. Item

CRO News

 @NesaNFierce: What should a CDMO do with 90 million Euros? Buy more CDMOs, as Recipharm announced it will do. Article | Follow @NesaNFierce

> SGS picks up testing company Vitrology for an undisclosed fee. News

> Pfizer's David Simmons joins PPD as new CEO and chairman. Story

> PRA expands European ops with new Dutch and British offices. More

> Quintiles survey shows U.S. and U.K. payers want to improve R&D with increased involvement. Item

Vaccines News

> Wishing you a happy HIV Vaccine Awareness Day. Report

> Vitamin D boosts TB shot as cancer therapy. Article

> DNA vaccine swats TB and HIV. News

> HIV vaccine carries its own adjuvant into clinical trials. Story

And Finally... Fever during pregnancy doubles the risk of autism or developmental delay, a new study finds. Report